In the United States, testicular germ cell tumors (TGCT) are the most common cancers in young men, with a peak incidence among those aged 25 to 34 years. The incidence of TGCT has more than doubled among white men in the United States over the past 30 years; similar increases in incidence rates have been observed in other populations of European ancestry^[@R1]--[@R3]^. Of note, the incidence of TGCT varies widely between populations and is much higher in individuals of European compared to African ancestry^[@R2]^. Established risk factors for TGCT include family history, cryptorchidism, adult height and prior TGCT history; several recent studies also have implicated marijuana use^[@R4]--[@R7]^. First degree relatives of affected men have been shown consistently to have an increased TGCT risk (5- to 19-fold for brothers and 2- to 4-fold for fathers)^[@R8]--[@R11]^, the highest for any cancer. Further, the estimated heritability of TGCT is third among all cancers, with genetic effects estimated to account for 25% of TGCT susceptibility^[@R12]^. These observations, coupled with twin studies^[@R13]--[@R15]^, support a strong genetic component contributing to TGCT susceptibility.

Despite the greatly increased relative risk of TGCT in family members, candidate gene and linkage approaches yielded little progress in identifying specific genetic risk factors. Initially, two independent genome wide association studies (GWAS) identified allele variation within *KITLG* on 12q22 as the strongest genetic risk factor for TGCT, with a per allele odds ratio (OR) greater than 3^[@R16],[@R17]^. Variants on 5p15.33 (*TERT-* two independent loci*),* 5q31.3 (*SPRY4),* 6p21.3 (*BAK1)*, 9p24.3 (*DMRT1-* two independent loci), and 12p13.1 (*ATF7IP)* also have been associated with TGCT risk^[@R16]--[@R21]^. The per allele ORs for the identified TGCT susceptibility alleles are in large part higher than those identified for other cancers, which may be due, in part, to the homogeneity of the disease, as all TGCT are thought to arise from the primordial germ cell^[@R22],[@R23]^. Multiple additional loci are expected to contribute to susceptibility as has been shown for cancers of lower heritability^[@R24]^. Combining multiple GWAS represents a step to increase power to detect additional genetic risk factors failing to reach genome-wide significance in individual studies.

We performed a meta-analysis of the most promising 340 SNPs (after excluding previously reported loci) observed in the adjusted pooled analysis of the combined NCI scan (STEED, US Servicemen's Testicular Tumor Environmental and Endocrine Determinants Study; and FTCS, NCI Familial Testicular Cancer Study) with the previously reported University of Pennsylvania (UPENN) TGCT scan (**Online Methods**). Allelic ORs for known loci are shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} for the combined NCI scan. Forty SNPs from nine loci had *P* values below 10^−4^, of which 12 localized to the *MAD1L1* gene locus (7p22.2) (details of correlation between NCI and UPENN study for top 40 SNPs in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The most significant SNP marker from each of nine loci, plus eight additional markers were selected for replication (n=17). An *in silico* analysis of these 17 SNPs was performed in the GWAS data from the University of Southern California (USC) and the UK Testicular Cancer Collaboration (UKTCC)^[@R18]^, followed by genotyping in four additional TGCT case-control studies from: Fred Hutchinson Cancer Center (Adult Testicular Lifestyle and Blood Specimen \[ATLAS\] study), University of Pennsylvania (Testicular Cancer in Philadelphia Area Counties \[TestPAC\] study), Oslo University Hospital-Radium Hospital, Norway (OUHRH), and MD Anderson Cancer Center (MDA). Details of each study are included in the [Supplementary Note](#SD1){ref-type="supplementary-material"}. The combined analysis included 4,142 TGCT cases and 9,566 controls ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). In the combined meta-analysis, we observed four new loci significantly associated with TGCT (*P* value \< 5×10^−8^) ([Table 1](#T1){ref-type="table"}; [Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

The most significant 4q22.2 SNP marker, rs17021463, is located within the intron of the hematopoietic prostaglandin D synthase gene, *HPGDS* (*P* = 1.11×10^−8^, OR 1.19, 95%CI 1.12--1.26) ([Figure 1A](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). In mice, *hpgds* is expressed in the early embryonic male gonad and appears to regulate nuclear localization of the sox9 protein^[@R25]^. Disruption of *hpgds* leads to modification of the phenotype of *apc*^Min/+^ mice^[@R26]^. Seventy-one surrogate markers highly correlate with *HPGDS* rs17021463 (*r^2^* ≥ 0.8, 1000 Genomes CEU data, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Notably, rs35744894 (*r^2^* = 0.87) changes a DMRT2 binding motif ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}); variation in *DMRT1* has been associated with TGCT risk^[@R19]^.

Fifty-three of 71 surrogate markers that were highly correlated with *HPGDS* rs17021463 (*r^2^* ≥ 0.8, 1000 Genomes CEU data, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}) across a 200kb window mapped within or near an adjacent gene, *SMARCAD1* (SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1). SMARCAD1 is a chromatin remodeler, which restores silenced heterochromatin domains in dividing cells and participates in DNA damage response^[@R27],[@R28]^. Homozygous mutant mice display developmental defects, including impaired fertility^[@R29]^. Surrogate markers included one nonsynonymous substitution, rs7439869, at codon 301 (*r^2^* = 0.93, 1000 Genomes CEU, T\>C, Val\>Ala). Although it is predicted to be tolerated by PolyPhen2^[@R30]^, it changes an OCT4 (*POUF5F1*) and SOX4 binding motif ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). OCT4 is a transcription factor, which regulates pluripotency in a number of cell types, including primordial germ cells, and is expressed in TGCT^[@R31]--[@R36]^.

We identified a locus on 7p22.3, harboring mitotic arrest deficient-like 1 (*MAD1L1*) gene, which encodes MAD1. The most significant SNP without study heterogeneity, rs12699477, localized in intron 17 (*P* = 5.59 × 10^−9^, OR 1.21, 95%CI (1.14--1.29)) ([Figure 1B](#F1){ref-type="fig"}). Of note, the risk allele (C) at rs12699477 is more prevalent in populations of European (29%) than those of African ancestry (8%) in 1000 Genomes^[@R37]^. MAD1 is a spindle assembly checkpoint protein that delays the onset of anaphase in the mitotic cell cycle until all sister chromatids achieve proper alignment and microtubule attachment, thereby preventing aneuploidy and maintaining genomic stability^[@R38]^.

Among the 35 SNPs that are highly correlated with *MAD1L1* rs12699477 (*r^2^* ≥ 0.7, 1000 Genomes CEU data, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}), rs1801368 is a missense mutation at codon 558 (G\>A, Arg\>His) that resides in the *MAD1L1* second leucine zipper domain. Arg558His has been reported to be associated with lung cancer risk^[@R39]^ and may lead to reduced binding of MAD2 to MAD1, resulting in decreased proficiency in enforcing mitotic arrest^[@R40]^. We observed additional statistically significant associations with TGCT for neighboring SNPs in the *MAD1L1* region, including rs10275045 (*P*=3.78×10^−10^, OR 1.20, 95%CI (1.13--1.27)) and rs3778991 (*P*=6.73×10^−10^, OR 1.21, 95%CI (1.14--1.28)). However, both displayed significant study heterogeneity ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The *r^2^* between our strongest signal at rs12699477 and these markers is 0.66 and 0.50, respectively, in the STEED controls. A conditional analysis resulted in a marked attenuation of the signal, supporting a single TGCT susceptibility locus across *MAD1L1* on 7q22.3 ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}).

We observed a significant TGCT association with rs4888262 on 16q22.3 (*P* = 5.15×10^−12^, OR 1.26, 95%CI 1.18--1.34), which is a synonymous SNP in codon 404 (G\>A, Thr) of the ring finger WD domain 3 (*RFWD3*) ([Table 1](#T1){ref-type="table"}, [Figure 1C](#F1){ref-type="fig"}). RFWD3 is an E3 ubiquitin ligase that positively regulates p53 stability by forming a RFWD3-MDM2-p53 complex, thereby protecting p53 from degradation by MDM2 polyubiquitination^[@R41],[@R42]^. Within the LD interval are SNPs that map to two additional genes, the golgi glycoprotein 1 (*GLG1*) and mixed lineage kinase domain-like (*MLKL*); the latter of which has been recently identified as a key of mediator of TNF-induced necrosis, downstream of receptor interacting protein kinase 3 (RIP3)^[@R43],[@R44]^ ([Figure 1C](#F1){ref-type="fig"}). We note that rs3851729, which is highly correlated with rs4888262 (*r^2^* = 0.77, 1000 Genomes CEU), maps to a highly conserved sequence in the 3′ UTR of *GLG1*; similarly, rs4072222 (*r^2^* = 0.87, 1000 Genomes CEU) maps to an intron of *MLKL* ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Both susceptibility variants are *cis*-eQTLs that influence *MLKL* and *RFWD3* expression in monocytes^[@R45]^.

We identified two highly correlated SNPs (*r^2^* = 0.74 in the STEED controls) on 17q22, rs9905704 (*P* = 4.32×10^−13^, OR 1.27, 95%CI 1.18--1.33) and rs7221274 (*P* = 4.04×10^−9^, OR 1.20, 95%CI 1.12--1.28) ([Table 1](#T1){ref-type="table"}, [Figure 1D](#F1){ref-type="fig"}). In a conditional analysis, the signal at one SNP was markedly attenuated by the other, indicating a single 17q22 TGCT susceptibility locus ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Within this LD block are at least six plausible candidate genes: *RAD51C* (RAD51 homolog C \[S. cerevisiae\]), *TEX14* (testis expressed 14), *PPM1E* (protein phosphatase, Mg2+/Mn2+ dependent, 1E), *SEPT4* (septin 4), *TRIM37* (tripartite motif containing 37), and *SKA2* (spindle and kinetochore associated complex subunit 2) ([Figure 1D](#F1){ref-type="fig"}). Proteins encoded by these candidate genes, except for *SKA2*, have been implicated as having roles in spermatogenesis^[@R46]--[@R51]^. *RAD51C* is a DNA repair gene, in which rare mutations confer susceptibly to ovarian cancer^[@R52],[@R53]^. Of male *rad51c^ko/neo^* mice, approximately one-third were found to be infertile due to impaired spermatogenesis^[@R49]^. TEX14 is an essential component of germ cell intercellular bridges, evolutionarily conserved structures from invertebrates to humans that allows clonal development of daughter cells in syncytium; targeted disruption of *Tex14* results in male sterility in mice^[@R48]^. TEX14 also has been implicated as an important component of kinetochores (KTs) and interacts with MAD1^[@R54]^. *PPM1E* encodes a phosphatase that dephosphorylates to switch-off CaMK4 (calcium/calmodulin-dependent protein kinase IV), deficiency of which causes infertility in mice^[@R50],[@R55]^. *TRIM37* encodes a RING-B-box-coiled-coil protein; rare mutations in this gene cause the autosomal recessive disease mulibrey nanism (MUL; MIM 253250)^[@R56]^, in which adult males have testicular failure^[@R57]^. Three SNPs - rs8077332, rs11652713, and rs9898048 - map within *TRIM37* and are in perfect LD with rs7221274 (*r^2^* = 1, 1000 Genomes CEU, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}); all are *cis*-eQTL affecting *RAD51C* expression in monocytes^[@R45]^. Thus, fine mapping and functional studies will be required to elucidate the biological basis of the association signal in this interval on 17q22.

In our meta-analysis of GWAS studies, we have identified four new TGCT susceptibility loci at 4q22, 7q22, 16q22.3, and 17q22. In total, 10 loci now have been conclusively associated with TGCT susceptibility. The four newly identified susceptibility alleles account for 2% of the risk to the brothers and 3% of risk to the sons of TGCT patients, increasing the cumulative total of 12 susceptibility alleles (two susceptibility alleles from *TERT-CLPTM1L* \[5p15\] and two from *DMRT1* locus \[9p24\]) to 14% and 21% of the risk to brothers and sons, respectively. Based on the high heritability of TGCT, more than one hundred additional loci are expected to be discovered^[@R24]^. Notably, the allelic ORs associated with these novel loci are in the range of 1.2 to 1.3, continuing the trend of identifying loci with higher odds ratios for TGCT than for other cancer types^[@R23]^.

Interestingly, each locus harbors biologically plausible candidate genes implicating several pathways -- most strikingly, spermatogenesis and male germ cell development (*HPGDS, SMARCAD1, SEPT4, TEX14, RAD51C, PPM1E, TRIM37*), chromosomal segregation (*MAD1L1, TEX14, SKA2*), and DNA damage response (*SMARCAD1, RFWD3, RAD51C*). None of the four newly identified loci have been previously implicated in GWAS of other cancers, further supporting that there are distinct pathways and regions implicated in TGCT susceptibility; however rare mutations in *RAD51C* have been implicated in ovarian cancer susceptibility^[@R53]^. TGCT susceptibility is particularly unique in that many of the associated genes affect male germ cell development and differentiation, thus emphasizing the potential detrimental effect that inherited variation in this developmental process can have on the tumorigenic potential of the primordial germ cell.

This study is the first to implicate variation within genes involved in chromosomal segregation as associated with cancer susceptibility. TGCT karyotypes are unique among cancers, in that nearly all carry the same chromosomal aberration, a gain of 12p, most often in the form of an isochromosome, which is considered essential for tumor development^[@R58]--[@R60]^. Variation in these genes may lead to chromosomal instability and facilitate the development of aneuploidy. Numerous potential regulatory SNPs were identified, suggesting that newly identified associations might be mediated by plausible genes within each locus, which warrant further fine-mapping and functional studies to elucidate the biological bases of the TGCT susceptibility regions. Studies of the genetic basis of TGCT continue to provide novel insights into this unique disease with high heritability.

ONLINE METHODS {#S1}
==============

Studies {#S2}
-------

Detailed characteristics of the study populations are described in both the [Supplementary Note](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Subjects used in the current study are all of European descent and data from each study were collected and analyzed in accordance with local ethical permissions and informed consent. Three studies (STEED, FTCS, and UPENN) were included in the discovery meta-analysis, and six studies contributed to replication by *de novo* genotyping (TestPAC, ATLAS, OUHRH, and MDA) or *in silico* look-up in existing data (UKTCC and USC).

Genotyping and quality control {#S3}
------------------------------

Genotype quality control metrics for the reported GWAS scans (UPENN and UKTCC) were previously described^[@R18],[@R19]^. Genotype quality control metrics for STEED, FTCS, and USC are described in [Supplementary Note](#SD1){ref-type="supplementary-material"}^[@R61]^. OUHRH and MDA studies were genotyped using the 5′ exonuclease assay (TaqMan^™^) and the ABI prism 7900HT sequence detection system, all according to the manufacturer's instructions, across several genotyping centers. Primers and probes were supplied directly by Applied Biosystems as Assays-By-Design^™^. Technical validation was performed in the HapMap samples (n=270) with greater than 99% genotype concordance. TestPAC and ATLAS studies conducted genotyping using the iPLEX mass array platform (Sequenom, Inc.) following manufacturer's protocol. Assays at all genotyping centers included at least four negative controls and 2--5% duplicates on each plate. Standard quality control protocol was implemented; SNP call rate \> 95%, no deviation from Hardy-Weinberg equilibrium in controls at *P*\<0.00001, \<2% discordance between genotypes in duplicate had to be fulfilled and cluster plots for SNPs that were close to failing any of the QC criteria were re-examined centrally.

Statistical analysis {#S4}
--------------------

Two genome-wide scans from the National Cancer Institute (STEED and FTCS) were analyzed as a combined dataset using a logistic regression model for trend effect adjusted for age, study, and additionally for one eigenvector (only one with p \< 0.05) to account for population stratification in this European population. From the top 500 SNPs by trend *P* values from the NCI scan excluding previously reported ones, 340 SNPs were selected based on the availability of surrogates (*r^2^* \> 0.6) in the previous TGCT GWAS scan from the University of Pennsylvania. Since SNP content differs between the Illumina and Affymetrix platforms, the best correlated surrogate per each marker was paired to perform a discovery meta-analysis (111 SNPs, direct match; 229 SNPs, surrogate match). From the discovery meta-analysis, 17 of 40 SNPs with *P* values \< 10^−4^ were selected for follow up in the remaining studies. *In silico* follow-up was done in the USC and UKTCC scans, whereas additional genotyping was done in TestPAC, ATLAS, OUHRH and MDA studies ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Not all markers were available for replication efforts from all sites (see [Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

The meta-analysis was conducted using the suite of tools in GLU (Genotyping Library and Utilities) software, combining study-specific odds ratio (OR) estimates using a fixed effects model, which used the inverse-variance method to estimate the combined OR and its 95% confidence intervals (CIs). To assess existence of heterogeneity among studies, Cochran's Q statistic was used to calculate *P* for heterogeneity.

Recombination hotspots were identified in the vicinity of the novel TGCT associated loci using SequenceLDhot^[@R62]^, a program that uses the approximate marginal likelihood method^[@R63]^ and calculates likelihood ratio statistics at a set of possible hotspots. We tested five unique sets of 100 control samples drawn from STEED. PHASE v2.1 program was used to calculate background recombination rates^[@R64],[@R65]^ and LD heatmap was visualized in *r^2^* using snp.plotter program^[@R66]^.

The relative risk attributable to a set of SNPs (*λ*) was estimated using the following formula^[@R67]^

$$\lambda = \prod\limits_{i = 1}^{n}\frac{p_{i}{(p_{i}r_{2i} + q_{i}r_{1i})}^{2} + q_{i}{(p_{i}r_{1i} + q_{i}r_{0i})}^{2}}{{(p_{i}^{2}r_{2i} + 2p_{i}q_{i}r_{1i} + q_{i}^{2}r_{0i})}^{2}}$$ where *q~t~* is the minor allele frequency of SNP~i~ and *p~i~* = 1 − *q~i~*. SNP specific risks for rare homozygotes, heterozygotes, and common homozygotes are denoted by *r*~0~*~i~*, *r*~1~*~i~*, and *r*~2~*~i~*, respectively. The NCI controls (n=1,140) were used to estimate minor allele frequencies and odds ratio estimates from SNP association analyses were used to estimate relative risks. This formula assumes the effects of all SNPs in the set are multiplicative. The proportion of familial risk attributable to a set of SNPs was calculated as $\frac{\log\lambda}{\log\lambda_{0}}$, where *λ*~0~ is the familial relative risk estimated from TGCT epidemiological studies (*λ*~0~ =4 for affected father, *λ*~0~ =8 for affected brother)^[@R68]^.

Genomic annotation {#S5}
------------------

Genomic annotation on high LD surrogates (*r^2^* ≥ 0.8, 1000 Genomes CEU) of 5 SNPs (rs17021463, rs12699477, rs4888262, rs9905704, and rs7221274) from the four TGCT susceptibility loci identified in the current study was conducted using ENCODE tools -- HaploReg^[@R69]^ and RegulomeDB^[@R70]^ ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). rs12699477 did not have surrogates with *r^2^* ≥ 0.8 threshold, thus we lowered the threshold to 0.7 for surrogates, and then conducted annotation. All surrogates were queried in RegulomeDB browser to cross examine predicted regulatory DNA elements such as regions of DNase hypersensitivity, binding sites of transcription factors, and promoter regions that have been biochemically characterized to regulation transcription. Summaries of each SNP analysis by RegulomeDB browser expressed in scores are added to [Supplementary Table 5](#SD1){ref-type="supplementary-material"}. To predict potential regulatory SNPs, we assessed SNPs that meet one of the following criteria - 1) conserved (GERP and/or Siphy); 2) present in a promoter or DNase hypersensitivity region; or 3) predicted to have a cis eQTL or having a RegulomeDB score of ≤ 3. Twenty-nine SNPs that passed one of these criteria also changed a motif, and are annotated further with the motif of interest and their log-odds (LOD) motif score for the specific SNP of interest in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Two SNPs in 3′-UTR regions were evaluated using SNP Function Prediction for changes in miRNA binding sites and are included in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}.
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###### Recombination plot and linkage disequilibrium structure for the four new TGCT susceptibility regions at 4q22.2, 7p22.3, 16q22.3 and 17q22 (a--d)

Regional plots of association results, recombination hotspots and linkage disequilibrium for the (a) 4q22.2--22.3:94,904,738--95,514,609, (b) 7p22.3:1,651,900--2,479,029, (c) 16q23.1:74,179,928--74,812,676 and (d) 17q22--23.1:56,083,934--57,680,480 TGCT susceptibility loci. (a--d) Combined meta-analysis results are shown as red diamonds with rs numbers labeled, and the NCI scan in gray. For each plot, −log10*P* values (y axis, left) of the SNPs are shown according to their chromosomal positions (x axis). Linkage disequilibrium structure based on NCI controls (n=1,188) was visualized by snp.plotter software. The line graph shows likelihood ratio statistics (y axis, right) for recombination hotspot by SequenceLDhot software and five different colors represent 5 tests of 100 controls from NCI without resampling. Physical locations of each region are based on NCBI Build 37 of the human genome.
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###### 

Meta-analysis identified novel loci associated with testicular germ cell tumor

  SNP[1](#TFN1){ref-type="table-fn"}   Nearby genes   Study[2](#TFN2){ref-type="table-fn"}   Cases   Controls   EAF[3](#TFN4){ref-type="table-fn"}   Allelic OR (95% CI)   *P* value        *P* for heterogeneity
  ------------------------------------ -------------- -------------------------------------- ------- ---------- ------------------------------------ --------------------- ---------------- -----------------------
  rs17021463                           *HPGDS*        NCI                                    582     1055       0.475                                1.33 (1.14--1.55)     2.12 × 10^−4^    
  G\|T                                 4q22.2         UPENN                                  349     919        0.433                                1.28 (1.07--1.53)     6.67 × 10^−3^    
                                                      *Discovery*                            931     1974                                            1.31 (1.16--1.47)     6.09 × 10^−6^    0.750
                                                                                                                                                                                            
                                                      UKTCC                                  979     4947       0.420                                1.19 (1.08--1.31)     5.66 × 10^−4^    
                                                      USC                                    358     258        0.428                                1.09 (0.82--1.46)     0.464            
                                                      OUHRH                                  798     377        0.399                                1.16 (0.98--1.39)     0.092            
                                                      TestPAC                                267     575        0.417                                1.14 (0.92--1.41)     0.225            
                                                      ATLAS                                  297     664        0.420                                1.11 (0.91--1.35)     0.292            
                                                      MDA                                    236     351        0.412                                1.01 (0.79--1.27)     0.960            
                                                      *Replication*                          2935    7172                                            1.15 (1.07--1.23)     7.01 × 10^−5^    0.862
                                                                                                                                                                                            
                                                      *Combined*                             3866    9146                                            1.19 (1.12--1.26)     1.11 × 10^−8^    0.583
                                                                                                                                                                                            
  rs12699477                           *MAD1L1*       NCI                                    582     1056       0.412                                1.31 (1.13--1.52)     4.64 × 10^−4^    
  T\|C                                 7p22.3         UPENN                                  349     919        0.407                                1.37 (1.15--1.63)     4.25 × 10^−4^    
                                                      *Discovery*                            931     1975                                            1.34 (1.19--1.50)     7.16 × 10^−7^    0.704
                                                                                                                                                                                            
                                                      UKTCC                                  979     4947       0.380                                1.17 (1.06--1.30)     1.34 × 10^−3^    
                                                      USC                                    358     258        0.352                                1.32 (0.99--1.74)     0.024            
                                                      TestPAC                                266     573        0.375                                1.09 (0.88--1.35)     0.440            
                                                      ATLAS                                  298     671        0.373                                1.08 (0.89--1.32)     0.480            
                                                      *Replication*                          1901    6449                                            1.16 (1.07--1.25)     2.41 × 10^−4^    0.645
                                                                                                                                                                                            
                                                      *Combined*                             2832    8424                                            1.21 (1.14--1.29)     5.59 × 10^−9^    0.318
                                                                                                                                                                                            
  rs4888262                            *RFWD3*        NCI                                    582     1052       0.552                                1.36 (1.17--1.59)     9.12 × 10^−5^    
  T\|C                                 16q22.3        UPENN                                  349     919        0.498                                1.39 (1.16--1.67)     3.12 × 10^−4^    
                                                      *Discovery*                            931     1971                                            1.37 (1.22--1.54)     1.39 × 10^−7^    0.858
                                                                                                                                                                                            
                                                      UKTCC                                  957     4940       0.458                                1.22 (1.10--1.34)     1.02 × 10^−4^    
                                                      USC                                    358     258        0.440                                1.41 (1.09--1.83)     5.14 × 10^−3^    
                                                      TestPAC                                260     575        0.465                                1.12 (0.91--1.38)     0.2876           
                                                      ATLAS                                  295     649        0.495                                1.16 (0.95--1.41)     0.1328           
                                                      *Replication*                          1870    6422                                            1.21 (1.12--1.31)     1.62 × 10^−6^    0.568
                                                                                                                                                                                            
                                                      *Combined*                             2801    8393                                            1.26 (1.18--1.34)     5.15 × 10^−12^   0.397
                                                                                                                                                                                            
  rs9905704                            *TEX14*        NCI                                    582     1054       0.719                                1.37 (1.16--1.61)     1.88 × 10^−4^    
  G\|T                                 17q22          UPENN                                  349     919        0.663                                1.30 (1.08--1.56)     5.46 × 10^−3^    
                                                      *Discovery*                            931     1973                                            1.33 (1.19--1.52)     3.44 × 10^−6^    0.674
                                                                                                                                                                                            
                                                      UKTCC                                  979     4947       0.680                                1.28 (1.16--1.43)     3.65 × 10^−6^    
                                                      USC                                    358     258        0.649                                1.35 (1.08--1.72)     0.017            
                                                      OUHRH                                  802     382        0.695                                1.23 (1.02--1.49)     0.028            
                                                      TestPAC                                259     575        0.669                                1.14 (0.91--1.43)     0.253            
                                                      ATLAS                                  300     666        0.669                                1.09 (0.88--1.33)     0.403            
                                                      MDA                                    234     351        0.672                                1.15 (0.89--1.47)     0.273            
                                                      *Replication*                          2932    7179                                            1.23 (1.15--1.32)     1.37 × 10^−8^    0.628
                                                                                                                                                                                            
                                                      *Combined*                             3863    9152                                            1.27 (1.18--1.33)     4.32 × 10^−13^   0.668
  rs7221274                            *PPM1E*        NCI                                    582     1056       0.660                                1.39 (1.19--1.61)     3.56 × 10^−5^    
  G\|A                                 17q22          UPENN                                  349     919        0.598                                1.19 (1.00--1.43)     0.053            
                                                      *Discovery*                            931     1975                                            1.30 (1.16--1.47)     7.79 × 10^−6^    0.197
                                                                                                                                                                                            
                                                      UKTCC                                  979     4947       0.620                                1.23 (1.12--1.37)     3.08 × 10^−5^    
                                                      USC                                    358     258        0.558                                1.37 (0.87--2.13)     9.43 × 10^−3^    
                                                      OUHRH                                  802     380        0.630                                1.22 (1.02--1.47)     0.029            
                                                      TestPAC                                243     538        0.612                                1.01 (0.81--1.27)     0.890            
                                                      ATLAS                                  301     671        0.604                                1.00 (0.83--1.22)     0.989            
                                                      MDA                                    215     351        0.615                                1.05 (0.83--1.33)     0.682            
                                                      *Replication*                          2898    7145                                            1.16 (1.09--1.25)     3.27 × 10^−5^    0.228
                                                                                                                                                                                            
                                                      *Combined*                             3829    9120                                            1.20 (1.12--1.28)     4.04 × 10^−9^    0.130

SNP genotype depicted as reference allele\|effect allele

NCI depicts combined analysis results of the two GWAS scans STEED and FTCS performed at NCI

Discovery depicts initial meta-analysis of NCI and UPENN and Replication depicts meta-analysis of the rest

EAF depicts effect allele frequency in control
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